Maxwell Skor
Stock Analyst at Morgan Stanley
(2.93)
# 1,656
Out of 5,105 analysts
7
Total ratings
66.67%
Success rate
44.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Initiates: Overweight | $190 | $220.65 | -13.89% | 1 | Oct 16, 2025 | |
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $197.01 | -26.91% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $220.42 | +13.42% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $5.14 | +133.46% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.01 | +890.10% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $2.32 | +53.02% | 2 | Nov 20, 2024 |
Cidara Therapeutics
Oct 16, 2025
Initiates: Overweight
Price Target: $190
Current: $220.65
Upside: -13.89%
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $197.01
Upside: -26.91%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $220.42
Upside: +13.42%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $5.14
Upside: +133.46%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.01
Upside: +890.10%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $2.32
Upside: +53.02%